Hot Pursuit     20-Apr-24
Biocon gets nod from SAHPRA for Tacrolimus capsules
Biocon announced that it has received an approval from South African Health Products Regulatory Authority (SAHPRA) for their vertically integrated, complex drug product Tacrolimus capsule in South Africa.
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported consolidated net profit of Rs 660 crore in Q3 FY24 as compared with net loss of Rs 41.8 crore posted in Q3 FY23. Revenue from operations jumped 34.43% year on year (YoY) to Rs 3,953.7 crore in the quarter ended 31 December 2023.

The scrip fell 2.10% to end at Rs 261.70 on Friday, 19 April 2024.

Previous News
  Stock Alert: Force Motors, Biocon, Adani Wilmar, JSW Energy, GE Vernova, ONGC,
 ( Market Commentary - Stock Alert 05-Mar-25   08:36 )
  Biocon gains after arm launches YESINTEK Biosimilar in U.S. Market
 ( Hot Pursuit - 25-Feb-25   09:37 )
  Biocon
 ( Results - Analysis 17-May-24   10:41 )
  Biocon’s board OKs to raise Rs 4,500-cr
 ( Hot Pursuit - 24-Apr-25   08:11 )
  Board of Biocon approves fund raising up to Rs 4,500 cr
 ( Corporate News - 23-Apr-25   20:05 )
  Biocon
 ( Results - Analysis 01-Feb-25   16:10 )
  Biocon's Ustekinumab biosimilar gets marketing authorisation for EU region
 ( Hot Pursuit - 18-Feb-25   09:30 )
  Biocon Biologics inks a settlement and license agreement with Regeneron
 ( Corporate News - 15-Apr-25   09:29 )
  Biocon Ltd rises for third consecutive session
 ( Hot Pursuit - 24-Apr-24   13:05 )
  Biocon
 ( Results - Analysis 13-Nov-23   12:15 )
  Biocon gains as board to mull fund raising on Jan 27
 ( Hot Pursuit - 23-Jan-25   11:06 )
Other Stories
  Kamat Hotels Q4 PAT surges 412% YoY to Rs 11 cr
  26-Apr-25   16:21
  Bank of Maharashtra Q4 PAT climbs 23% YoY to Rs 1,493 crore
  26-Apr-25   15:34
  Oracle Financial Services Software Q4 PAT up 19% QoQ
  26-Apr-25   14:28
  Force Motors Q4 PAT surges 210% YoY to Rs 435 cr; declares dividend of Rs 40/sh
  26-Apr-25   14:02
  L&T Finance Q4 PAT rises 15% YoY to Rs 636 crore
  26-Apr-25   13:31
  RBL Bank PAT drops 81% YoY to Rs 69 crore in Q4 FY25; provisions zoom by 90% YoY
  26-Apr-25   12:12
  Tejas Networks reports dismal Q4 outcome
  26-Apr-25   11:54
  Zydus Life gets 6 observations from USFDA for API plant
  26-Apr-25   11:02
  RIL Q4 PAT rises 6.4% YoY
  26-Apr-25   10:05
  Tata Technologies Q4 PAT climbs 12% QoQ to Rs 189 cr
  25-Apr-25   17:34
Back Top